高危冒烟型多发性骨髓瘤:早期治疗与观察争议综述
冒烟型多发性骨髓瘤(SMM)异质性强,仅高危患者2年内进展风险≥50%。但总生存获益未确定,精准识别高危患者仍困难,管理应风险适应和以患者为中心。
要点
- 高危SMM定义:2年内进展为MM风险≥50%。
- 达雷妥尤单抗单药获首批高危SMM适应症,基于AQUILA试验。
- 早期治疗延迟进展,但总生存获益未确定,需防过度治疗。
核心结论
- 达雷妥尤单抗获批后,SMM管理应风险适应和以患者为中心,观察仍适用于部分患者,早期治疗应考虑用于精选的高危和超高危个体。
研究设计与样本
- 本文为综述,汇总随机III期试验及AQUILA试验等证据,讨论高危SMM早期治疗与观察的争议。
主要发现
- 随机III期试验一致显示早期治疗延迟SMM进展为MM。
- 现代监测和先进影像下,多数进展事件无症状,不可逆终末器官损害不常见。
- 早期治疗的总生存获益仍不确定,尤其在MM进展时四药联合方案可用的时代。
- 精准识别真正高危患者仍困难,引发过度治疗担忧。
关键数值与推荐
- 高危SMM定义为2年内进展为MM风险≥50%。
临床怎么用
- SMM管理应风险适应:观察适用于部分患者,早期治疗考虑用于精选的高危和超高危个体。
- 达雷妥尤单抗单药可作为高危SMM的早期治疗选择。
局限性
- 早期治疗的总生存获益仍不确定。
- 精准识别真正高危患者存在困难,可能过度治疗。
- 强化方案、双特异性抗体和CAR-T细胞的长期获益与安全性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Smoldering multiple myeloma (SMM) is an asymptomatic but biologically heterogeneous plasma cell disorder with a variable risk of progression to multiple myeloma (MM). Accurate risk stratification is essential as only a subset of patients-defined as high-risk SMM -faces a ≥50% risk of progression within 2 years. Contemporary approaches integrating clinical variables, dynamic biomarkers, genomic alterations, and immune profiling have improved risk assessment although some limitations remain. The therapeutic paradigm of SMM is evolving. Randomized phase III trials have consistently shown that early treatment delays progression to MM. Most recently, daratumumab monotherapy became the first approved treatment for high-risk-SMM following the AQUILA trial, which demonstrated a significant progression-free survival benefit (hazard ratio [HR], 0.49 [95% CI, 0.36 to 0.67], P < .001) and a trend toward improved overall survival (OS; HR, 0.52 [95% CI, 0.27 to 0.98]) versus observation. This approval challenges the traditional watch-and-wait approach and establishes early intervention as a validated option for selected patients. However, important uncertainties persist. With modern surveillance and advanced imaging, most progression events are asymptomatic and irreversible end-organ damage is uncommon. OS benefit from early treatment remains inconclusive, particularly in the era of quadruplet regimens available at MM progression. In addition, difficulties in precisely identifying truly high-risk patients raise concerns about overtreatment. Emerging data from intensive regimens, bispecific antibodies, and chimeric antigen receptor -T cell therapies suggest that deep and durable responses-and possibly cure-may be achievable in selected patients with high-risk-SMM, but long-term benefit and safety require further study. In conclusion, following the approval of daratumumab, SMM management should be risk-adapted and patient-centered: observation remains appropriate for some patients, while early treatment should be considered for carefully selected high- and ultrahigh-risk individuals.
引用
- Mateos MV, Gustine J, Puertas B, et al. High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation. J Clin Oncol. 2026. PMID: 42535861. doi:10.1200/JCO-26-00236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。